Ignite Creation Date:
2024-05-05 @ 10:40 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01161602
Status:
COMPLETED
Last Update Posted:
2011-09-21
First Post:
2010-07-12
Brief Title:
A Study to Evaluate the Safety Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease GERD
Sponsor:
Edusa Pharmaceuticals Inc
Organization:
Edusa Pharmaceuticals Inc
Study Overview
Official Title:
A Phase IIa Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability and Pharmacodynamics of Multiple Dose Levels of Pumosetrag in Patients With Symptoms Associated With Gastroesophageal Reflux Disease GERD Receiving a Standard Refluxogenic Meal
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if pumosetrag is effective in treating Gastroesophageal Reflux Disease GERD symptoms in patients who have a history of GERD symptoms and are currently taking an acid suppression therapy such as a Proton Pump Inhibitor PPI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None